Piper Sandler began coverage on shares of Kestra Medical Technologies (NASDAQ:KMTS - Free Report) in a research note released on Monday morning, Marketbeat reports. The brokerage issued an overweight rating and a $27.00 target price on the stock.
Several other equities analysts have also issued reports on KMTS. Stifel Nicolaus began coverage on Kestra Medical Technologies in a research report on Monday. They issued a "buy" rating and a $28.00 price target for the company. The Goldman Sachs Group initiated coverage on shares of Kestra Medical Technologies in a report on Monday. They issued a "neutral" rating and a $24.00 target price for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $27.67.
Get Our Latest Research Report on Kestra Medical Technologies
Kestra Medical Technologies Stock Down 3.0 %
KMTS stock traded down $0.73 on Monday, reaching $23.29. 62,011 shares of the company traded hands, compared to its average volume of 275,704. Kestra Medical Technologies has a one year low of $20.00 and a one year high of $26.06.
About Kestra Medical Technologies
(
Get Free Report)
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.
Featured Stories
Before you consider Kestra Medical Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kestra Medical Technologies wasn't on the list.
While Kestra Medical Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
